Mylan, Fujifilm win EU okay for copy of AbbVie's Humira

05:03 EDT 20 Sep 2018 | Reuters

Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine.

Original Article: Mylan, Fujifilm win EU okay for copy of AbbVie's Humira

More From BioPortfolio on "Mylan, Fujifilm win EU okay for copy of AbbVie's Humira"